5
Pharmaceutical preparations, namely, rna therapeutics for use in the treatment of cancer, hiv, hepatitis a, hepatitis b, influenza, measles, neurodegenerative diseases, transthyretin (ttr)-mediated amyloidosis (attr), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary attr amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis b virus infection, hepatitis d virus infection, chronic liver infection; pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, hiv, hepatitis a, hepatitis b, influenza, measles, neurodegenerative diseases, transthyretin (ttr)-mediated amyloidosis (attr), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary attr amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis b virus infection, hepatitis d virus infection, chronic liver infection; pharmaceutical preparations, namely, rna therapeutics; pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes